Get a better understanding of growth expectations and the ultimate potential market size

Dublin, January 13, 2023 — (GLOBE NEWSWIRE). “Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates” A report has been added ResearchAndMarkets.com’s offering.

The success of Immuno-oncology Therapeutics is largely due to the companion diagnostics. It is a new segment in the diagnostics industry, and it is not small. It promises to explode in popularity.

Histology, genomics, and liquid biopsy are merging. The new strategy for conquering cancer is complicated and involves a complex network of diagnostic companies, pharmaceutical companies, and instrumentation suppliers. This approach appears to be working well and shows great promise.

There is a revolution underway in cancer treatment. A new therapy that relies on the body’s natural immune system is proving to be extremely successful. However, diagnostics and biomarkers are crucial for selecting the right treatment.

Technology is moving faster than the markets. The health care industry has seen a significant impact. Tumor Mutational Burden Are there Checkpoint Inhibitors Cytokines?

Learn about technology in simple terms that simplify the technical jargon. Discover the potential pitfalls and opportunities. This comprehensive new report provides insight into market potential and growth expectations.

We cover the following key topics:

1 Market Guides
1.1 Situation Analysis & Impact of COVID-19 Pandemic
1.2 Guide for Marketing Executives and Staff
1.3 Guide for Management Consultants and Investment Analysts

2 Introduction and Market Definition
2.1 What are Immuno-Oncology Diagnostics and How Do They Work?
2.2 Immuno-oncology: The looming cure
2.2.1 Immunooncology Diagnostics Plays an Important Role
2.3 Definition of Market
2.3.1 Market Size
2.3.2 Currency
2.3.3 years
2.4 Methodology
2.4.1 Authors
2.4.2 Sources
2.5 Perspective: Healthcare and IVD Industry.
2.5.1 Global Healthcare Spending
2.5.2 Diagnostics spending
2.5.3 The Role of Insurance in Diagnostics

3 Immunotherapy-Guide to Immune Technologies
3.1 The Immune System
3.1.1 Innate immune system
3.1.1.1 Surface barriers
3.1.1.2 Inflammation
3.1.1.3 The Complement System
3.1.1.4 Cellular barriers
3.1.1.5 Natural killer cells
3.1.2 Adaptive immune system
3.1.2.1 Lymphocytes
3.1.2.2 Killer T cells
3.1.2.3 Helper T cells
3.1.2.4 Gamma delta T cells
3.1.2.5 Antibodies and Lymphocytes
3.1.3 Tumor immunology- The immune surveillance system
3.2 Immuno Oncology Diagnostics
3.2.1 Assays for Checkpoint
3.2.1.1 Outlook on Checkpoint Assays
3.2.2 Cytokine Tests
3.2.3 Genomic Germline
3.2.4 Genomic Tumour
3.2.5 Microenvironment for Tumors
3.2.6 Other Diagnostics

4 Industry Overview
4.1 Market Players
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Supplier of Genomic Instrumentation
4.1.4 Suppliers of Viewing and Cell Separation Instrumentation
4.1.5 Pharmaceutical/Reagent Supplier
4.1.6 Independent Testing Lab
4.1.7 Public National/Regional Lab
4.1.8 Hospital laboratory
4.1.9 Physician Lab
4.1.10 Audit body
4.1.11 Certification Organization

5 Market Trends
5.1 Growth Factors
5.1.1 Potential outcomes
5.1.2 Companion Diagnostics
5.1.3 Funding
5.1.4 Technology Environment
5.1.5 Target Solutions
5.2 Factors Limiting Growth
5.2.1 Diagnostics: A Complex Role
5.2.2 Clinical Trials
5.2.3 Protocols
5.3 Diagnostic Technology Development
5.3.1. Combinations – Complexity and Issues
5.3.2 Diagnostics play a changing role
5.3.3 Multiplexing, Foundation One
5.3.4 The Disruption Dynamic
5.3.5 The Race for Biomarkers
5.3.6 The Next Five Years

6 Recent Advancements in Immuno-Oncology Diagnostics for Cancer
6.1 Recent Developments: Importance and Use of This Section
6.1.1 The Importance These Developments
6.1.2 How to Use the Section
6.2 Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes
6.3 Qiagen, OncXerna Close Companion Dx Development Deal
Bladder Cancer Treatment Guided by the 6.4 Natera Test
Boost Immuno Oncology Activity with 6.5 Veracyte Halio Purchase
6.6 Freenome New Dx Possibilities
Potential for Immunotherapy Response Prediction using 6.7 Oncocyte Data
6.8 OncoDNA uses HalioDx for Expanding into North America
6.9 Adaptive Biotechnologies, Q2 Solution Agreement for ImmunoSeq Assay
6.10 Qiagen Expands Immuno Oncology Portfolio
6.11 Immune profiling system redirected to fight COVID-19
6.12 IncellDx awarded PD-L1 Detection patent
6.13 FDA Approves CDx for Trastuzumab
6.14 Promega Nabs Ce Mark for Microsatellite Incability IVD
6.15 ArcherDx is a partner with AstraZeneca in Immuno-Oncology
6.16 Germline results guide Precision Therapy
FDA Approves 6.17 Agilent PD-1 Assay
6.18 Bayer, OrigiMed Form Companion Diagnostic Development Alliance
6.19 Biome to Create Microbiome Biomarker for Cancer Immunotherapy
6.20 SkylineDx and BioInvent collaborate to characterize predictive immunological signatures
6.21 Biocare Medical launches 7 Novel IVD Antibodies
6.22 Oncocyte to Purchase Insight Genetics at $12M
6.23 Novigenix & BioLizard will develop NGS Based Diagnostic Algorithm
6.24 Biodesix & Immodulon collaborate for pancreatic cancer treatment
6.25 Generex to meld with NuGenerex Immuno Oncology
6.26 Cellgen Diagnostics and Genomic Testing Partner to Develop Companion Diagnostics For Cancer Therapies
6.27 Hematogenix launches FDA-approved Immuno-oncology Test to Test for Triple Negative Breast Carcinoma
6.28 Icon Acquires MolecularMD

7 Profiles of Key Immuno-oncology Companies
7.1 10x Genomics, Inc.
7.2 Abbott Diagnostics
7.3 AccuraGen, Inc.
7.4 Adaptive Biotechnologies
7.5 Aethlon Medical
7.6 Agena Bioscience, Inc
7.7 Agilent/Dako
7.8 Anchor Dx
7.9 ANGLE plc
7.10 ApoCell, Inc.
7.11 ARUP Laboratories
7.12 Asuragen
7.13 AVIVA Biosciences
7.14 Baylor Miraca Genetics Laboratories
7.15 Beckman Coulter Diagnostics
7.16 Becton, Dickinson and Company
7.17 BGI Genomics Co. Ltd
7.18 Bioarray Genetics
7.19 Biocartis
7.20 Biocept, Inc.
7.21 Biodesix Inc.
7.22 BioFluidica
7.23 BioGenex
7.24 BioIVT
7.25 Biolidics Ltd
7.26 bioMerieux Diagnostics
7.27 Bioneer Corporation
7.28 Bio-Rad Laboratories, Inc.
7.29 Bio-Reference Laboratories
7.30 Bio-Techne
7.31 Bioview
7.32 Bolidics
7.33.
7.34 Bristol-Myers Squibb
7.35 Burning Rock
7.36 Genetics for Cancer
7.37 Caris Molecular Diagnostics
7.38 Castle Biosciences, Inc.
7.39 CellMax Life
7.40 Cepheid (Danaher)
7.41 Charles River Laboratories
7.42 Chronix Biomedical
7.43 Circulogene
7.44 Clinical Genomics
7.45 Cynvenio
7.46 Cytolumina Industries Corp.
7.47 CytoTrack
7.48 Datar Cancer Genetics Limited
7.49 Diagnologix LLC
7.50 Diasorin S.p.A.
7.51 Enzo Biochem
7.52 Epic Sciences
7.53 Epigenomics AG
7.54 Eurofins Scientific
7.55 Exosome Diagnostics
7.56 Exosome Sciences
7.57 Fabric Genomics
7.58 Fluidigm Corp
7.59 Fluxion Biology Sciences
7.60 Foundation Medicine
7.61 Freenome
7.62 FUJIFILM Wako Diagnostics
7.63 GeneFirst Ltd.
7.64 Genetron Holdings
7.65 GenomOncology
7.66 GILUPI Nanomedizin
7.67 Grail, Inc.
7.68 Guardant Health
7.69 HalioDx
7.70 HansaBiomed
7.71 HeiScreen
7.72 Helomics
7.73 Horizon Discovery
7.74 HTG Molecular Diagnostics
7.75 iCellate
7.76 Illumina
7.77 Incell Dx
7.78 Inivata
7.79 Integrated Diagnostics
7.80 Invitae Corporation
7.81 Invivogen
7.82 Invivoscribe
7.83 Janssen Diagnostics
7.84 MDNA Life SCIENCES, Inc.
7.85 MDx Health
7.86 Menarini Silicon Biosystems
7.87 Millipore Sigma
7.88 Miltenyi Biotec
7.89 MIODx
7.90miR Scientific
7.91 Molecular MD
7.92 MyCartis
7.93 Myriad Genetics/Myriad RBM
7.94 NantHealth, Inc.
7.95 Natera
7.96 NeoGenomics
7.97 New Oncology
7.98 NGeneBio
7.99 Novogene Bioinformatics Technology Co., Ltd.
7.100 Oncocytes
7.101 OncoDNA
7.102 Ortho Clinical Diagnostics
7.103 Oxford Nanopore Technologies
7.104 Panagene
7.105 Perkin Elmer
7.106 Personal Genome Diagnostics
7.107 Personalis
7.108 Precipio
7.109 PrecisionMed
7.110 Promega
7.111 Qiagen Gmbh
7.112 Rarecells SAS
7.113 RareCyte
7.114 Roche Molecular Diagnostics
7.115 Screencell
7.116 Sense biodetection
7.117 Serametrix
7.118 Siemens Healthineers
7.119 Silicon Biosystems
7.120 simfo GmbH
7.121 Singlera Genomics Inc.
7.122 Singulomics
7.123 SkylineDx
7.124 Stratos Genomics
7.125 Sysmex Inostics
7.126 Tempus Labors, Inc.
7.127 Thermo Fisher Scientific Inc.
7.128 Thrive Earlier Detection
7.129 Todos Medical
7.130 Trovagene
7.131 Volition
7.132 Vortex Biosciences

8 The Global Market for Immuno-Oncology Diagnostics
8.1 Global Market Overview, Country
8.2 Global Market By Assay Type – Overview

9 Global Immuno-Oncology Diagnostic Markets by Assay Type
9.1 Checkpoint
9.2 Cytokine
9.3 Germline Genetic
9.4 Genetic Tumor
9.5 Tumor Microenvironment

10 Appendices
10.1 FDA Cancer Drug Aprovals by Year
10.2 Clinical trials started 2010-2016
10.3 Prevalence of cancer treatments
10.4 United States Medicare System: 2021 Schedule of Clinical Laboratory Fees

This report has more information, visit https://www.researchandmarkets.com/r/5d09if

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We offer the most current data on the global and regional markets, top companies, and new products.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900